Biostax Corp (BTAX)

[locicat1]

Excellent post! As you indicated, the November 30, 2017 Shareholder Update Letter indicates " The FDA Meeting has confirmed a meeting (note redundancy) for January of 2018 to discuss final Phase 2b/3 protocols for both pediatric and adult Crohn's Disease."

As you so correctly state, at least the company at this point should minimally acknowledge that such a confirmed meeting did indeed occur and more information to follow. Even though not definitive, such an important progress milestone input would be most beneficial to shareholders and the investment community as you described.